Synedgen, Inc.
Claremont, CA Doing business as Synedgen Inc.
- UEI
- HX79BD6YQ521
- CAGE
- 5JGC8
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1420 N Claremont Blvd #105d, Claremont, CA 91711, USA
- Website
- synedgen.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Advance the development of PAAG17G (drug product: MIIST305), a once daily, orally administered, GUT-restricted drug,… | Office of the Assistant Secretary for Preparedness and Response | $18,828,663 | |
| Sbir phase III proposal no. JW230017 titled, "optimized, field-stable glycopolymer-mimicking polysaccharide to prevent… | Defense Health Agency | $2,297,415 | |
| Award of synedgen's DHA sbir phase III follow-on medical r & d contract for "development of technologies that control… | Medical Command | $549,725 | |
| Optimized glycopolymer-mimicking polysaccharide to provide barrier function and restore gastrointestinal integrity and… | Defense Health Agency | $4,445,860 | |
| Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision. | National Eye Institute | $2,103,845 |
About Synedgen, Inc.
Synedgen, Inc. is a for-profit corporate entity registered in SAM.gov, specializing in regenerative medicine, wound healing, and advanced pharmaceutical research and development. Located in Claremont, California, the company focuses on developing innovative medical technologies and drug products that address complex medical challenges, particularly in the areas of radiation injury mitigation, gastrointestinal health, and tissue repair. As a small business, Synedgen has established itself as a strategic partner for federal agencies seeking cutting-edge biomedical solutions.
Through federal contract awards, Synedgen has secured multiple significant contracts from agencies including the Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) and the Defense Health Agency (DHA). These contracts, predominantly set aside for small businesses, center on developing advanced medical technologies to prevent and mitigate radiation-induced injuries. Notable contract work includes a $119,642,445 contract to develop PAAG17G (MIIST305), an orally administered drug designed to reduce mortality and morbidity from acute ionizing radiation exposure, and a $2,297,415 SBIR Phase III contract to develop field-stable glycopolymer-mimicking polysaccharides for preventing radiation or nuclear injury. The company has also received a $549,725 contract from the Department of the Army Medical Command to develop technologies controlling scar formation after burn injuries.
In the realm of federal grants, Synedgen has been involved in both prime and sub-grant awards focused on advanced medical research. A prime federal grant from the Defense Health Agency (Award ID: W81XWH2210869) supports research on developing glycopolymer-mimicking polysaccharides to restore gastrointestinal integrity in inflammatory bowel diseases. Additionally, the company serves as a critical subrecipient in a grant awarded to Columbia University, where Synedgen's role involves synthesizing their proprietary therapeutic MIIST305 under good manufacturing practices, consulting on experimental protocols, and providing scientific feedback. These grant activities demonstrate Synedgen's expertise in developing sophisticated medical interventions, particularly in areas of gastrointestinal health, radiation mitigation, and regenerative medicine.
Quick answers
What is Synedgen, Inc.'s UEI?
Synedgen, Inc.'s Unique Entity ID (UEI) in SAM.gov is HX79BD6YQ521.
What is Synedgen, Inc.'s CAGE code?
Synedgen, Inc.'s CAGE code is 5JGC8.
What is Synedgen, Inc.'s primary NAICS code?
Synedgen, Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Synedgen, Inc. located?
Synedgen, Inc.'s physical address in SAM.gov is 1420 N Claremont Blvd #105d, Claremont, CA 91711, USA.
Is Synedgen, Inc. registered in SAM.gov?
Yes. Synedgen, Inc.'s SAM.gov registration is active through November 11, 2026.
What is Synedgen, Inc.'s most recent federal award?
Synedgen, Inc.'s most recent federal contract award is Advance the development of PAAG17G (drug product: MIIST305), a once daily, orally administered, GUT-restricted drug,… (75A50124C00047), from Office of the Assistant Secretary for Preparedness and Response, on September 30, 2024.
On GovTribe
See Synedgen, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors